A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase…
Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 SOUTH SAN FRANCISCO,…
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing…
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring…
Randomized Disrupt PAD III Study Finds Superior Vessel Preparation Leads to Excellent Long-Term Outcomes and…
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER,…
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual…
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a…
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR),…
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3…
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected…
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad…
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
UB-VV100 preclinical safety data demonstrates overall low risk for off target transduction and has a…
PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”),…
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM”…
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns…
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3…